Pulse Biosciences, Inc. Appoints Paul A. LaViolette as Chief Executive Officer

Pulse Biosciences, Inc. recently announced the appointment of Paul A. LaViolette as the Chief Executive Officer and President of the company, effective January 9, 2025. Mr. LaViolette, who previously served as the Co-Chairman of the Board, brings valuable experience in the healthcare industry, having held significant roles at various global healthcare corporations and medical technology startups.

With 15 years of executive experience at Boston Scientific Corporation, including roles such as Chief Operating Officer and Group President, Mr. LaViolette’s expertise complements Pulse Biosciences’ strategic goals. He also served in leadership roles at CR Bard and Medtronic. Currently, he is a director at Edwards Lifesciences and the Chairman of the Innovation Advisory Board at Mass General Brigham.

In conjunction with his new role, Mr. LaViolette has entered into an Employment Agreement with Pulse Biosciences, outlining his responsibilities and compensation. The agreement includes an annual base salary of $725,000, an annual target bonus, and participation in employee benefit plans. Additionally, the company awarded Mr. LaViolette stock options to purchase up to 1,500,000 shares of common stock.

The appointment of Mr. LaViolette marks a significant milestone for Pulse Biosciences, reflecting the company’s commitment to strengthening its leadership team. The Employment Agreement and Mr. LaViolette’s background suggest a promising future as Pulse Biosciences continues to focus on innovation and growth in the healthcare sector.

For more details regarding the appointment and the Employment Agreement, interested parties can refer to the official document filed by Pulse Biosciences with the Securities and Exchange Commission.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Pulse Biosciences’s 8K filing here.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.